Cargando…

Estimation of Vaccine Efficacy and Critical Vaccination Coverage in Partially Observed Outbreaks

Classical approaches to estimate vaccine efficacy are based on the assumption that a person's risk of infection does not depend on the infection status of others. This assumption is untenable for infectious disease data where such dependencies abound. We present a novel approach to estimating v...

Descripción completa

Detalles Bibliográficos
Autores principales: van Boven, Michiel, Ruijs, Wilhelmina L. M., Wallinga, Jacco, O'Neill, Philip D., Hahné, Susan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3642050/
https://www.ncbi.nlm.nih.gov/pubmed/23658512
http://dx.doi.org/10.1371/journal.pcbi.1003061
_version_ 1782268089467928576
author van Boven, Michiel
Ruijs, Wilhelmina L. M.
Wallinga, Jacco
O'Neill, Philip D.
Hahné, Susan
author_facet van Boven, Michiel
Ruijs, Wilhelmina L. M.
Wallinga, Jacco
O'Neill, Philip D.
Hahné, Susan
author_sort van Boven, Michiel
collection PubMed
description Classical approaches to estimate vaccine efficacy are based on the assumption that a person's risk of infection does not depend on the infection status of others. This assumption is untenable for infectious disease data where such dependencies abound. We present a novel approach to estimating vaccine efficacy in a Bayesian framework using disease transmission models. The methodology is applied to outbreaks of mumps in primary schools in the Netherlands. The total study population consisted of 2,493 children in ten primary schools, of which 510 (20%) were known to have been infected, and 832 (33%) had unknown infection status. The apparent vaccination coverage ranged from 12% to 93%, and the apparent infection attack rate varied from 1% to 76%. Our analyses show that vaccination reduces the probability of infection per contact substantially but not perfectly ([Image: see text] = 0.933; 95CrI: 0.908–0.954). Mumps virus appears to be moderately transmissible in the school setting, with each case yielding an estimated 2.5 secondary cases in an unvaccinated population ([Image: see text] = 2.49; 95%CrI: 2.36–2.63), resulting in moderate estimates of the critical vaccination coverage (64.2%; 95%CrI: 61.7–66.7%). The indirect benefits of vaccination are highest in populations with vaccination coverage just below the critical vaccination coverage. In these populations, it is estimated that almost two infections can be prevented per vaccination. We discuss the implications for the optimal control of mumps in heterogeneously vaccinated populations.
format Online
Article
Text
id pubmed-3642050
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-36420502013-05-08 Estimation of Vaccine Efficacy and Critical Vaccination Coverage in Partially Observed Outbreaks van Boven, Michiel Ruijs, Wilhelmina L. M. Wallinga, Jacco O'Neill, Philip D. Hahné, Susan PLoS Comput Biol Research Article Classical approaches to estimate vaccine efficacy are based on the assumption that a person's risk of infection does not depend on the infection status of others. This assumption is untenable for infectious disease data where such dependencies abound. We present a novel approach to estimating vaccine efficacy in a Bayesian framework using disease transmission models. The methodology is applied to outbreaks of mumps in primary schools in the Netherlands. The total study population consisted of 2,493 children in ten primary schools, of which 510 (20%) were known to have been infected, and 832 (33%) had unknown infection status. The apparent vaccination coverage ranged from 12% to 93%, and the apparent infection attack rate varied from 1% to 76%. Our analyses show that vaccination reduces the probability of infection per contact substantially but not perfectly ([Image: see text] = 0.933; 95CrI: 0.908–0.954). Mumps virus appears to be moderately transmissible in the school setting, with each case yielding an estimated 2.5 secondary cases in an unvaccinated population ([Image: see text] = 2.49; 95%CrI: 2.36–2.63), resulting in moderate estimates of the critical vaccination coverage (64.2%; 95%CrI: 61.7–66.7%). The indirect benefits of vaccination are highest in populations with vaccination coverage just below the critical vaccination coverage. In these populations, it is estimated that almost two infections can be prevented per vaccination. We discuss the implications for the optimal control of mumps in heterogeneously vaccinated populations. Public Library of Science 2013-05-02 /pmc/articles/PMC3642050/ /pubmed/23658512 http://dx.doi.org/10.1371/journal.pcbi.1003061 Text en © 2013 van Boven et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
van Boven, Michiel
Ruijs, Wilhelmina L. M.
Wallinga, Jacco
O'Neill, Philip D.
Hahné, Susan
Estimation of Vaccine Efficacy and Critical Vaccination Coverage in Partially Observed Outbreaks
title Estimation of Vaccine Efficacy and Critical Vaccination Coverage in Partially Observed Outbreaks
title_full Estimation of Vaccine Efficacy and Critical Vaccination Coverage in Partially Observed Outbreaks
title_fullStr Estimation of Vaccine Efficacy and Critical Vaccination Coverage in Partially Observed Outbreaks
title_full_unstemmed Estimation of Vaccine Efficacy and Critical Vaccination Coverage in Partially Observed Outbreaks
title_short Estimation of Vaccine Efficacy and Critical Vaccination Coverage in Partially Observed Outbreaks
title_sort estimation of vaccine efficacy and critical vaccination coverage in partially observed outbreaks
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3642050/
https://www.ncbi.nlm.nih.gov/pubmed/23658512
http://dx.doi.org/10.1371/journal.pcbi.1003061
work_keys_str_mv AT vanbovenmichiel estimationofvaccineefficacyandcriticalvaccinationcoverageinpartiallyobservedoutbreaks
AT ruijswilhelminalm estimationofvaccineefficacyandcriticalvaccinationcoverageinpartiallyobservedoutbreaks
AT wallingajacco estimationofvaccineefficacyandcriticalvaccinationcoverageinpartiallyobservedoutbreaks
AT oneillphilipd estimationofvaccineefficacyandcriticalvaccinationcoverageinpartiallyobservedoutbreaks
AT hahnesusan estimationofvaccineefficacyandcriticalvaccinationcoverageinpartiallyobservedoutbreaks